Products for Research Use Only
RegisterLogin

Nepafenac (Standard)

CAT: 0804-HY-17357R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17357R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Nepafenac (AHR 9434; AL 6515) (Standard) is the analytical standard of Nepafenac. This product is intended for research and analytical applications. Nepafenac, a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC50 of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC50 = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite Amfenac (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE₂. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries.
CAS Number
78281-72-8
Product Name Alternative
AHR 9434 (Standard) ; AL 6515 (Standard)
UNSPSC
12352005
Target
COX; Endogenous Metabolite; Prostaglandin Receptor; Reference Standards
Type
Reference Standards
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; Others
Field of Research
Cancer; Endocrinology; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/nepafenac-standard.html
Smiles
O=C(N)CC1=CC=CC(C(C2=CC=CC=C2)=O)=C1N
Molecular Formula
C15H14N2O2
Molecular Weight
254.28
References & Citations
[1]Gamache DA, Graff G, Brady MT et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24 (4) :357-70.|[2]Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24 (4) :371-84.|[3]Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006 Feb;22 (2) :397-404.|[4]Marshall JC, Fernandes BF, Di Cesare S et al. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis. 2007 Sep;28 (9) :2053-8.|[5]Singh R, Alpern L, Jaffe GJ et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259-69.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Related Products

CatalogName
HY-17357-01Nepafenac
HY-17357S-01Nepafenac-d5
HY-P2274RArgifin (Standard)
HY-N9362REmodinanthrone (Standard)
HY-N7948RIsomaltotetraose (Standard)
HY-N7640RDeoxylimonin (Standard)
HY-N7617RToralactone (Standard)
HY-N7541RAntrodin A (Standard)
HY-N6739RBeauvericin (Standard)
HY-N6687RCalcimycin (Standard)

Alternative Products

CatalogName
A2890-100Nepafenac

Popular Products